Holen Sie sich die Stockscreener-App
105.30
0.47%
-0.50
Handel nachbörslich:
105.30
Schlusskurs vom Vortag:
$105.80
Offen:
$105.42
24-Stunden-Volumen:
503.27K
Relative Volume:
0.71
Marktkapitalisierung:
$4.79B
Einnahmen:
$1.33B
Nettoeinkommen (Verlust:
$97.31M
KGV:
51.83
EPS:
2.0317
Netto-Cashflow:
$260.44M
1W Leistung:
-1.42%
1M Leistung:
+1.29%
6M Leistung:
+91.70%
1J Leistung:
+116.04%
1-Tages-Spanne:
$103.54
$105.78
1-Wochen-Bereich:
$103.54
$108.22
52-Wochen-Spanne:
$47.72
$110.45
Haemonetics Corp Stock (HAE) Company Profile
Firmenname
Haemonetics Corp
Sektor
Branche
Telefon
(781) 848-7100
Adresse
125 SUMMER STREET, BOSTON, MA
Compare HAE vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HAE
Haemonetics Corp
|
105.30 | 4.79B | 1.33B | 97.31M | 260.44M | 2.0317 |
ABT
Abbott Laboratories
|
98.83 | 175.27B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
86.29 | 113.38B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
275.39 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.65 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.32 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
Haemonetics Corp Stock (HAE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-15 | Herabstufung | Needham | Buy → Hold |
| 2025-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-08-11 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-08-08 | Bestätigt | Barrington Research | Outperform |
| 2025-08-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-07-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-06-26 | Eingeleitet | Robert W. Baird | Outperform |
| 2025-02-07 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-12-06 | Eingeleitet | JP Morgan | Overweight |
| 2024-11-08 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-09-13 | Eingeleitet | CL King | Buy |
| 2024-09-11 | Eingeleitet | BofA Securities | Neutral |
| 2024-09-10 | Eingeleitet | BTIG Research | Buy |
| 2024-06-12 | Hochstufung | Needham | Hold → Buy |
| 2022-10-13 | Eingeleitet | Mizuho | Buy |
| 2022-01-27 | Herabstufung | Needham | Buy → Hold |
| 2021-12-15 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-08-17 | Fortgesetzt | Raymond James | Outperform |
| 2021-06-17 | Eingeleitet | Citigroup | Buy |
| 2021-05-14 | Hochstufung | CJS Securities | Market Perform → Market Outperform |
| 2021-04-20 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | Herabstufung | CJS Securities | Market Outperform → Market Perform |
| 2021-02-03 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2021-01-21 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2020-11-05 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2020-05-06 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2020-03-31 | Hochstufung | CJS Securities | Market Perform → Market Outperform |
| 2020-01-10 | Eingeleitet | Needham | Buy |
| 2019-08-07 | Bestätigt | Barrington Research | Outperform |
| 2019-05-14 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-05-08 | Bestätigt | Barrington Research | Outperform |
| 2018-08-09 | Bestätigt | Barrington Research | Outperform |
| 2018-02-07 | Bestätigt | Barrington Research | Outperform |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-11-08 | Bestätigt | Barrington Research | Outperform |
| 2017-08-08 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2017-07-13 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2017-02-07 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2016-11-08 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2016-11-07 | Bestätigt | The Benchmark Company | Hold |
| 2016-09-20 | Herabstufung | CJS Securities | Market Outperform → Market Perform |
| 2016-08-15 | Herabstufung | Sidoti | Buy → Neutral |
| 2016-08-02 | Bestätigt | Jefferies | Buy |
| 2016-08-02 | Bestätigt | The Benchmark Company | Hold |
Alle ansehen
Haemonetics Corp Aktie (HAE) Neueste Nachrichten
Haemonetics (NYSE:HAE): A Quality Investing Candidate Built on Durable Fundamentals - ChartMill
Haemonetics Corporation (HAE) Stock Price, News, Quote & History - Yahoo! Finance Canada
HAE6089008 Bond Profile: Coupon and Redemption - TradingView
Haemonetics Corporation (HAE) Stock Forecasts - Yahoo Finance
Haemonetics (HAE) Following Margin Expansion Narrative Looks Fairly Valued - simplywall.st
Haemonetics (HAE) Could Be 66% Undervalued After Margin Expansion Focus - Yahoo Finance
HAE - Finviz
Haemonetics Stock Price Forecast. Should You Buy HAE? - StockInvest.us
Haemonetics stock hits 52-week high at 109.6 USD By Investing.com - Investing.com South Africa
Haemonetics Shares Rise After Citigroup Upgrade - marketscreener.com
HAE Upgraded by Citigroup -- Price Target Raised to $123 - GuruFocus
Haemonetics stock hits 52-week high at 109.6 USD - Investing.com
Haemonetics stock upgraded at Bank of America (HAE:NYSE) - Seeking Alpha
Citigroup Upgrades Haemonetics to Buy From Neutral, Adjusts Price Target to $123 From $92 - Yahoo Finance
Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics - GlobeNewswire
Orchestra BioMed Obtains $6.1 Million Milestone Payment From Haemonetics' Acquisition of Vivasure - Yahoo Finance
Haemonetics (HAE) Stock Dropped, So What Is Driving Attention Now? - simplywall.st
Q1 2027 Haemonetics Corp Earnings Call Transcript - GuruFocus
Haemonetics Corporation (HAE) Peer Comparison – Compare with Others - Value Research
HAE Maintained by Raymond James -- Price Target Raised to $125 - GuruFocus
Haemonetics Corporation (HAE) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Haemonetics (HAE) Stock Looks Reasonable On Cash Flow But Rich On Earnings - simplywall.st
Haemonetics (HAE) Q1 2027 Earnings Call Transcript - AOL.ca
Winners And Losers Of Q2: Haemonetics (NYSE:HAE) Vs The Rest Of The Medical Devices & SuppliesSpecialty Stocks - Yahoo Finance
HAE Maintained by Baird -- Price Target Raised to $119.00 - GuruFocus
Haemonetics grows recurring revenues with plasm... - Pluang
Robert W. Baird Issues Positive Forecast for Haemonetics (NYSE:HAE) Stock Price - MarketBeat
Haemonetics: Worth Speculating On This Recurring Medtech Plasma Model (NYSE:HAE) - Seeking Alpha
26,280 Shares in Haemonetics Corporation $HAE Acquired by Nierenberg Investment Management Company LLC - MarketBeat
Aurora Investment Counsel Acquires New Position in Haemonetics Corporation $HAE - MarketBeat
Haemonetics stock hits 52-week high at 106.64 USD By Investing.com - Investing.com South Africa
HAE Maintains by Barrington Research -- Price Target Raised to $118 - GuruFocus
HAEMONETICS CORP : BARRINGTON RESEARCH RAISES TARGET PRICE TO $118 FROM $95 - Bitget
Haemonetics stock hits 52-week high at 106.64 USD - Investing.com
Barrington Raises Price Target on Haemonetics to $118 From $95, Keeps Outperform Rating - marketscreener.com
Haemonetics Shares Hit New 52-Week High: What's Happening? - Sahm
Is Haemonetics’ (HAE) ESOP Shelf Move Reframing Its Balance Between Growth Investment and Shareholder Dilution? - simplywall.st
Haemonetics Corp (HAE) Shares Surge 15.9% -- What GF Score of 85 Tells Investors - GuruFocus
HAE Maintained by BTIG -- Price Target Raised to $110 - GuruFocus
Haemonetics (HAE) Stock Climbs As Analysts Hike Price Targets - StocksToTrade
Form 8K Haemonetics Corp For: 18 August By Investing.com - Investing.com Australia
Haemonetics Jumps as Investors Cheer Raised Fiscal 2027 Outlook - Quiver Quantitative
Finanzdaten der Haemonetics Corp-Aktie (HAE)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.75%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):